Medullary Thyroid Cancer: Options for Systemic Therapy of Metastatic Disease?
- 20 April 2006
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (11) , 1653-1655
- https://doi.org/10.1200/jco.2005.05.4106
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti–Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor GroupJournal of Clinical Oncology, 2006
- Intracellular Signal Transduction Pathway Proteins As Targets for Cancer TherapyJournal of Clinical Oncology, 2005
- The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasmsSurgery, 2004
- Diagnosis and management of medullary thyroid carcinomaClinics In Laboratory Medicine, 2004
- High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysisBlood, 2003
- Cyclooxygenase-2 inhibitors in colorectal cancerSeminars in Oncology, 2003
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Clinical review 44: Medullary thyroid carcinoma: recent progressJournal of Clinical Endocrinology & Metabolism, 1993
- Medullary Thyroid Carcinoma: Clinicopathologic Features and Long-Term Follow-Up of 65 Patients Treated During 1946 Through 1970Mayo Clinic Proceedings, 1992
- Chemotherapy of Thyroid Cancer with AdriamycinNew England Journal of Medicine, 1974